These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25405535)

  • 1. Identification of potential drugs for Parkinson's disease based on a sub-pathway method.
    Sun AG; Lin AQ; Huang SY; Huo D; Cong CH
    Int J Neurosci; 2016; 126(4):318-25. PubMed ID: 25405535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated microarray analysis provided a new insight of the pathogenesis of Parkinson's disease.
    Kong P; Lei P; Zhang S; Li D; Zhao J; Zhang B
    Neurosci Lett; 2018 Jan; 662():51-58. PubMed ID: 28965931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sub-pathway based method to identify candidate drugs for glioblastomas.
    Zheng YR; Kang K; Wang JJ
    Med Oncol; 2014 Sep; 31(9):182. PubMed ID: 25146669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of Parkinson's disease marker-based weighted protein-protein interaction network for prioritization of co-expressed genes.
    George G; Valiya Parambath S; Lokappa SB; Varkey J
    Gene; 2019 May; 697():67-77. PubMed ID: 30776463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated network analysis identifying potential novel drug candidates and targets for Parkinson's disease.
    Quan P; Wang K; Yan S; Wen S; Wei C; Zhang X; Cao J; Yao L
    Sci Rep; 2021 Jun; 11(1):13154. PubMed ID: 34162989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monte Carlo cross-validation analysis screens pathway cross-talk associated with Parkinson's disease.
    Li T; Tang W; Zhang L
    Neurol Sci; 2016 Aug; 37(8):1327-33. PubMed ID: 27146810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenome-based gene discovery provides information about Parkinson's disease drug targets.
    Chen Y; Xu R
    BMC Genomics; 2016 Aug; 17 Suppl 5(Suppl 5):493. PubMed ID: 27586503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational drug discovery design approaches for treating Parkinson's disease.
    Van der Schyf CJ
    Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression meta-analysis of Parkinson's disease and its relationship with Alzheimer's disease.
    Kelly J; Moyeed R; Carroll C; Albani D; Li X
    Mol Brain; 2019 Feb; 12(1):16. PubMed ID: 30819229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Network and Pathway-Based Analyses of Genes Associated with Parkinson's Disease.
    Hu Y; Pan Z; Hu Y; Zhang L; Wang J
    Mol Neurobiol; 2017 Aug; 54(6):4452-4465. PubMed ID: 27349437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression characteristics of peripheral blood genes reveal potential biomarkers and candidate therapeutic targets for Parkinson's disease.
    Chen W; Zhou D; Zhu N; Yan X; Jiang G; Zhao L
    Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):118-124. PubMed ID: 32415937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds.
    Zhang H; Bai L; He J; Zhong L; Duan X; Ouyang L; Zhu Y; Wang T; Zhang Y; Shi J
    Eur J Med Chem; 2017 Dec; 141():257-272. PubMed ID: 29031072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potential diagnostic biomarkers for Parkinson's disease.
    Jiang F; Wu Q; Sun S; Bi G; Guo L
    FEBS Open Bio; 2019 Aug; 9(8):1460-1468. PubMed ID: 31199560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candidate agents for pancreatic ductal adenocarcinoma identified by a sub-pathway based method.
    Lin Y; Jin Y; Lin LJ; Cao Y; Zhang Y; Chen SF; Zheng CQ
    Gene; 2014 May; 540(2):232-7. PubMed ID: 24561286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validating the Predicted Effect of Astemizole and Ketoconazole Using a Drosophila Model of Parkinson's Disease.
    Styczyńska-Soczka K; Zechini L; Zografos L
    Assay Drug Dev Technol; 2017 Apr; 15(3):106-112. PubMed ID: 28418693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the genetics of Parkinson's disease.
    Rosner S; Giladi N; Orr-Urtreger A
    Acta Pharmacol Sin; 2008 Jan; 29(1):21-34. PubMed ID: 18158863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bidirectional drug repositioning approach for Parkinson's disease through network-based inference.
    Rakshit H; Chatterjee P; Roy D
    Biochem Biophys Res Commun; 2015 Feb; 457(3):280-7. PubMed ID: 25576361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The identification of dysfunctional crosstalk of pathways in Parkinson disease.
    Diao H; Li X; Hu S
    Gene; 2013 Feb; 515(1):159-62. PubMed ID: 23178242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can parkin be a target for future treatment of Parkinson's disease?
    Kubo S; Hatano T; Takanashi M; Hattori N
    Expert Opin Ther Targets; 2013 Oct; 17(10):1133-44. PubMed ID: 23930597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sub-pathway based method to identify candidate agents for Ankylosing Spondylitis.
    Chen K; Zhao Y; Chen Y; Wang C; Chen Z; Bai Y; Zhu X; Li M
    Molecules; 2012 Oct; 17(10):12460-8. PubMed ID: 23090024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.